Cantor Fitzgerald, L. P. Eliem Therapeutics, Inc. Transaction History
Cantor Fitzgerald, L. P.
- $90.6 Billion
- Q2 2025
A detailed history of Cantor Fitzgerald, L. P. transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Cantor Fitzgerald, L. P. holds 2,502,531 shares of ELYM stock, worth $10.3 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,502,531
Previous 1,999,415
25.16%
Holding current value
$10.3 Million
Previous $8.22 Million
25.17%
% of portfolio
0.01%
Previous 0.18%
Shares
3 transactions
Others Institutions Holding ELYM
# of Institutions
68Shares Held
49.5MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA31.4MShares$129 Million2.82% of portfolio
-
Citigroup Inc1.61MShares$6.62 Million0.0% of portfolio
-
Affinity Asset Advisors, LLC New York, NY1.5MShares$6.17 Million1.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.33MShares$5.47 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT1.04MShares$4.27 Million0.15% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $109M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...